Key result
The wild-type A/A genotype of the BLMH gene was associated with significantly better long-term pulmonary function, including lower SGRQ scores (4.20 vs 11.90, p=0.035), compared to the mutated allele in ABVD-treated Hodgkin lymphoma patients.
Why the study?
Does the BLMH gene SNP A1450G influence late pulmonary toxicity in ABVD-treated Hodgkin lymphoma patients?
Observational (n=131)
No
Does the BLMH gene SNP A1450G influence late pulmonary toxicity in ABVD-treated Hodgkin lymphoma patients?
Absolute Event Rate: 4.2% vs 11.9%
p-value: p=0.035
The BLMH gene SNP A1450G mutated allele is associated with worse late pulmonary function in Hodgkin lymphoma patients treated with ABVD, suggesting a potential role for genetic screening to avoid bleomycin toxicity.
BACKGROUND: Bleomycin hydrolase (BLMH), an enzyme that inactivates bleomycin, may be a potential candidate that could influence pulmonary function in ABVD (doxorubicin, bleomycin, vinblastin, dacarbasine)-treated Hodgkin lymphoma (HL) patients. PATIENTS AND METHODS: We hypothesized that the BLMH gene SNP A1450G (rs1050565) influences BLMH activity and late pulmonary toxicity. St. George Respiratory Questionnaire, lung scintigraphy and spirometry were used to determine lung function. TaqMan genotyping assay was used to determine genotype distribution of 131 previously treated HL patients. RESULTS: Significantly more favorable results were seen in the wild-type A/A genotype group than those in the group containing the mutated allele: A/G+G/G in retrospective pulmonary tests of ABVD treated patients. CONCLUSION: Besides limitations of the current study, bleomycin pharmacokinetics should be further evaluated in patients with BLMH variations, hence identify those cases even in the frontline setting, where bleomycin should be omitted and replaced with targeted therapy.
No takes yet. Share an insight, caveat, or question.
Jóna et al. (2016) conducted an observational in Hodgkin lymphoma (n=131). BLMH gene SNP A1450G wild-type A/A genotype vs. BLMH gene SNP A1450G mutated A/G or G/G genotype was evaluated on St. George Respiratory Questionnaire (SGRQ) score in ABVD-treated patients (p=0.035). The wild-type A/A genotype of the BLMH gene was associated with significantly better long-term pulmonary function, including lower SGRQ scores (4.20 vs 11.90, p=0.035), compared to the mutated allele in ABVD-treated Hodgkin lymphoma patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: